Page last updated: 2024-09-27

tizoxanide

Description

tizoxanide: major metabolite of nitazoxanide; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID394397
CHEMBL ID1545
CHEBI ID169666
SCHEMBL ID375440
MeSH IDM0271929

Synonyms (47)

Synonym
CHEBI:169666
2-hydroxy-n-(5-nitro-1,3-thiazol-2-yl)benzamide
173903-47-4
ntzdes
nsc697856
(2-hydroxyphenyl)-n-(5-nitro-(1,3-thiazol-2-yl))carboxamide
desacetyl-nitazoxanide
2-hydroxy-n-(5-nitrothiazol-2-yl)benzamide
tizoxanide
NCI60_034936
TIZ ,
nsc-697856
CHEMBL1545
AKOS002765892
FT-0675256
2-hydroxy-n-(5-nitro-2-thiazolyl)-benzamide
2-hydroxy-n-(5-nitro-2-thiazolyl)benzamide
nsc 697856
S5394
unii-15kfg88uoj
15kfg88uoj ,
benzamide, 2-hydroxy-n-(5-nitro-2-thiazolyl)-
CS-3893
T3862
SCHEMBL375440
AC-35255
HY-12687
DTXSID40169680
mfcd07484970
J-010949
n-(5-nitro-2-thiazolyl) salicyl-amide
NCGC00388427-01
bdbm50557729
AS-10635
BCP08678
nsc-697856; nsc697856; nsc697856;desacetyl-nitazoxanide
Q6587134
CCG-267097
SB34253
NCGC00388427-02
A24812
N10827
BT165461
tizoxanide - 98%
EN300-244574
2-hydroxy-n-(5-nitro-thiazol-2-yl)-benzamide
Z1741970236

Drug Classes (1)

ClassDescription
salicylamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Signal transducer and activator of transcription 3Homo sapiens (human)IC50 (µMol)8.90000.02304.13789.9800AID1709758
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (76)

Processvia Protein(s)Taxonomy
positive regulation of vascular endothelial growth factor productionSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IISignal transducer and activator of transcription 3Homo sapiens (human)
temperature homeostasisSignal transducer and activator of transcription 3Homo sapiens (human)
eye photoreceptor cell differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
regulation of DNA-templated transcriptionSignal transducer and activator of transcription 3Homo sapiens (human)
regulation of transcription by RNA polymerase IISignal transducer and activator of transcription 3Homo sapiens (human)
protein import into nucleusSignal transducer and activator of transcription 3Homo sapiens (human)
inflammatory responseSignal transducer and activator of transcription 3Homo sapiens (human)
signal transductionSignal transducer and activator of transcription 3Homo sapiens (human)
transforming growth factor beta receptor signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATSignal transducer and activator of transcription 3Homo sapiens (human)
nervous system developmentSignal transducer and activator of transcription 3Homo sapiens (human)
cell population proliferationSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of cell population proliferationSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of autophagySignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of gene expressionSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of gene expressionSignal transducer and activator of transcription 3Homo sapiens (human)
phosphorylationSignal transducer and activator of transcription 3Homo sapiens (human)
cytokine-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
sexual reproductionSignal transducer and activator of transcription 3Homo sapiens (human)
cell differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of cell migrationSignal transducer and activator of transcription 3Homo sapiens (human)
intracellular receptor signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
response to estradiolSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of interleukin-1 beta productionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of interleukin-10 productionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of interleukin-6 productionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of interleukin-8 productionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of tumor necrosis factor productionSignal transducer and activator of transcription 3Homo sapiens (human)
cellular response to hormone stimulusSignal transducer and activator of transcription 3Homo sapiens (human)
leptin-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
somatic stem cell population maintenanceSignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-15-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-2-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-9-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-11-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
regulation of multicellular organism growthSignal transducer and activator of transcription 3Homo sapiens (human)
glucose homeostasisSignal transducer and activator of transcription 3Homo sapiens (human)
eating behaviorSignal transducer and activator of transcription 3Homo sapiens (human)
mRNA transcription by RNA polymerase IISignal transducer and activator of transcription 3Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionSignal transducer and activator of transcription 3Homo sapiens (human)
cellular response to leptin stimulusSignal transducer and activator of transcription 3Homo sapiens (human)
response to leptinSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of erythrocyte differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of Notch signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of angiogenesisSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of glycolytic processSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISignal transducer and activator of transcription 3Homo sapiens (human)
astrocyte differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of inflammatory responseSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activitySignal transducer and activator of transcription 3Homo sapiens (human)
regulation of cell cycleSignal transducer and activator of transcription 3Homo sapiens (human)
radial glial cell differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
retinal rod cell differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
regulation of feeding behaviorSignal transducer and activator of transcription 3Homo sapiens (human)
growth hormone receptor signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATSignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-6-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
T-helper 17 type immune responseSignal transducer and activator of transcription 3Homo sapiens (human)
T-helper 17 cell lineage commitmentSignal transducer and activator of transcription 3Homo sapiens (human)
energy homeostasisSignal transducer and activator of transcription 3Homo sapiens (human)
cellular response to interleukin-17Signal transducer and activator of transcription 3Homo sapiens (human)
cell surface receptor signaling pathway via STATSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of inflammatory response to woundingSignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-10-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of miRNA transcriptionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of metalloendopeptidase activitySignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of primary miRNA processingSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of stem cell differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of neuron migrationSignal transducer and activator of transcription 3Homo sapiens (human)
regulation of cell population proliferationSignal transducer and activator of transcription 3Homo sapiens (human)
response to peptide hormoneSignal transducer and activator of transcription 3Homo sapiens (human)
defense responseSignal transducer and activator of transcription 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingSignal transducer and activator of transcription 3Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingSignal transducer and activator of transcription 3Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificSignal transducer and activator of transcription 3Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificSignal transducer and activator of transcription 3Homo sapiens (human)
DNA bindingSignal transducer and activator of transcription 3Homo sapiens (human)
DNA-binding transcription factor activitySignal transducer and activator of transcription 3Homo sapiens (human)
nuclear receptor activitySignal transducer and activator of transcription 3Homo sapiens (human)
signaling receptor bindingSignal transducer and activator of transcription 3Homo sapiens (human)
protein bindingSignal transducer and activator of transcription 3Homo sapiens (human)
protein kinase bindingSignal transducer and activator of transcription 3Homo sapiens (human)
protein phosphatase bindingSignal transducer and activator of transcription 3Homo sapiens (human)
chromatin DNA bindingSignal transducer and activator of transcription 3Homo sapiens (human)
signaling adaptor activitySignal transducer and activator of transcription 3Homo sapiens (human)
identical protein bindingSignal transducer and activator of transcription 3Homo sapiens (human)
protein homodimerization activitySignal transducer and activator of transcription 3Homo sapiens (human)
protein dimerization activitySignal transducer and activator of transcription 3Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingSignal transducer and activator of transcription 3Homo sapiens (human)
primary miRNA bindingSignal transducer and activator of transcription 3Homo sapiens (human)
lncRNA bindingSignal transducer and activator of transcription 3Homo sapiens (human)
DNA-binding transcription factor bindingSignal transducer and activator of transcription 3Homo sapiens (human)
RNA sequestering activitySignal transducer and activator of transcription 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
nucleusSignal transducer and activator of transcription 3Homo sapiens (human)
nucleusSignal transducer and activator of transcription 3Homo sapiens (human)
nucleoplasmSignal transducer and activator of transcription 3Homo sapiens (human)
cytoplasmSignal transducer and activator of transcription 3Homo sapiens (human)
cytosolSignal transducer and activator of transcription 3Homo sapiens (human)
plasma membraneSignal transducer and activator of transcription 3Homo sapiens (human)
RNA polymerase II transcription regulator complexSignal transducer and activator of transcription 3Homo sapiens (human)
chromatinSignal transducer and activator of transcription 3Homo sapiens (human)
transcription regulator complexSignal transducer and activator of transcription 3Homo sapiens (human)
cytoplasmSignal transducer and activator of transcription 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (88)

Assay IDTitleYearJournalArticle
AID533320Selectivity Index, ratio of CC50 for NTZ-11 cell harboring HCV genotype 1b to EC50 for HCV genotype 1b in NTZ-11 replicon cell2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID432004Cmax in human plasma at 500 mg, po2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance.
AID1194390Giardicidal activity against Giardia intestinalis IMSS:0696:1 compound treated for 48 hrs followed by incubation for 48 hrs in compound-free medium by cell counting2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Synthesis of nitro(benzo)thiazole acetamides and in vitro antiprotozoal effect against amitochondriate parasites Giardia intestinalis and Trichomonas vaginalis.
AID533326Antiviral activity against HCV genotype 1b obtained from TIZ-9 cells infected in Huh7.5 cell assessed as viral-induced colony formation efficiency at 1 uM after 10 to 14 days in presence of 125 ug/ml G4182008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID546704Antimicrobial activity against Staphylococcus epidermidis CAV1005 by microdilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces.
AID1194391Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Synthesis of nitro(benzo)thiazole acetamides and in vitro antiprotozoal effect against amitochondriate parasites Giardia intestinalis and Trichomonas vaginalis.
AID618736Antimicrobial activity against non-replicating Mycobacterium tuberculosis2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H₃₇Rv.
AID1709760Cytotoxicity against human HEK 293T cells assessed as cell growth inhibition at 50 uM measured after 48 hrs by MTT assay
AID533322Antiviral activity against HCV genotype 1b obtained from RP7 cells infected in Huh7.5 cell assessed as viral-induced colony formation efficiency at 1 uM after 10 to 14 days in presence of 125 ug/ml G4182008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID341089Antimicrobial activity against Clostridium difficile clinical isolates by agar dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
AID1431066Drug level in Sprague-Dawley rat treated with Nitazoxanide in plasma at 30 mg/kg, po measured at 0.7 to 2.1 hrs post dose2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs.
AID533312Antiviral activity against HCV genotype 1b in replicon system2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID533323Antiviral activity against HCV genotype 1b obtained from RP7 cells infected in Huh7.5 cell assessed as viral-induced colony formation efficiency at 10 uM after 10 to 14 days in presence of 125 ug/ml G4182008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID598290Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Entamoeba histolytica HM1-IMSS2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID704589Drug metabolism in Mycobacterium tuberculosis H37Rv assessed as [13C]acetylation at 1 to 10 fold MIC after 16 hrs by LC/MS analysis
AID546984Antimicrobial activity against Staphylococcus epidermidis 9142 at 1 to 5 ug/ml by microplate assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces.
AID1709759Cytotoxicity against human HeLa cells assessed as inhibition of cell viability measured after 48 hrs by MTT assay
AID642460Cytotoxicity against human Huh7.5 cells after 3 days by neutral red dye assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication.
AID598282Antiprotozoan activity against Trichomonas vaginalis GT3 trophozoites after 48 hrs2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID1194392Inhibition of Giardia intestinalis fructose 1,6-bisphosphate aldolase at 400 nM after 2 hrs by spectrophotometry2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Synthesis of nitro(benzo)thiazole acetamides and in vitro antiprotozoal effect against amitochondriate parasites Giardia intestinalis and Trichomonas vaginalis.
AID642461Selectivity index, ratio of CC50 for human Huh7.5 cells to EC50 for HCV genotype 1a infected in human Huh7.5 cells2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication.
AID1431029Drug level in Sprague-Dawley rat treated with Nitazoxanide at 6 mg/kg, iv measured at 0.7 to 2.1 hrs post dose2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs.
AID533315Antiviral activity against HCV genotype 1b in TIZ-9 replicon cell after 4 days by blot hybridization analysis2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID546705Antimicrobial activity against Staphylococcus epidermidis 9142 at 25 ug/ml under aerobic condition by microdilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces.
AID546987Antimicrobial activity against Staphylococcus epidermidis 5179 under aerobic condition by microdilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces.
AID1431014Drug level in Sprague-Dawley rat treated with RM5061 at 30 mg/kg, po measured at 0.25 to 0.5 post dose2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs.
AID325505Inhibition of Giardia lamblia recombinant nitroreductase 1 (EAA43030.1) expressed in Escherichia coli at 5 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel Giardia lamblia nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides.
AID546981Plasma protein binding in healthy volunteers at 500 mg/kg, po administered as single dose2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces.
AID642456Antiviral activity against HCV genotype 1b infected in Ava5 cells assessed as inhibition of viral replication after 3 days by blot hybridization analysis2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication.
AID1709756Cytotoxicity against human HeLa cells assessed as inhibition of cell viability at 10 uM measured after 48 hrs by MTT assay
AID642458Selectivity index, ratio of CC50 for human Ava5 cells to EC50 for HCV genotype 1b infected in human Ava5 cells2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication.
AID546986Antimicrobial activity against Staphylococcus epidermidis 9142 under aerobic condition by microdilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces.
AID533314Antiviral activity against HCV genotype 1b in NTZ-11 replicon cell after 4 days by blot hybridization analysis2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID606883Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in extracellular viral DNA measured 24 hrs after last dose2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication.
AID606886Selectivity index, ratio CC50 for human HepG2(2.2.15) cells to EC90 for decrease in intracellular viral DNA in Hepatitis B virus infected human HepG2(2.2.15) cells2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication.
AID1444851Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of extracellular viral DNA level2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection.
AID606885Selectivity index, ratio CC50 for human HepG2(2.2.15) cells to EC90 for decrease in extracellular viral DNA in Hepatitis B virus infected human HepG2(2.2.15) cells2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication.
AID546706Antimicrobial activity against Staphylococcus epidermidis 5179 at 25 ug/ml under aerobic condition by microdilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces.
AID1431123Drug level in Sprague-Dawley rat plasma treated with RM-5061 at 10 to 75 mg/kg administered via oral gavage qd for 28 consecutive days2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs.
AID546988Antimicrobial activity against Staphylococcus epidermidis CAV1005 under aerobic condition by microdilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces.
AID1709757Selectivity index, ratio of inhibition of IL-6 induced STAT3 transcriptional activity to inhibition against HeLa cells assessed as reduction in cell viability at 10 uM
AID533316Cytotoxicity against human RP7 cell harboring HCV genotype 1b after 4 days by neutral red dye uptake assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID1431074Bioavailability in Sprague-Dawley rat at 6 mg/kg, iv administered as single dose2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs.
AID533324Antiviral activity against HCV genotype 1b obtained from NTZ-11 cells infected in Huh7.5 cell assessed as viral-induced colony formation efficiency at 1 uM after 10 to 14 days in presence of 125 ug/ml G4182008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID598287Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID598312Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Leishmania mexicana MHOM/MX/ISETGS2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID1431124Elimination half life in Sprague-Dawley rat assessed as tizoxanide level in plasma at 10 to 75 mg/kg administered via oral gavage qd for 28 consecutive days2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs.
AID598285Antitrypanosomal activity against Trypanosoma cruzi MHOM/MX/1994/Ninoa epimastigotes after 72 hrs by neubauer chamber2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID533325Antiviral activity against HCV genotype 1b obtained from NTZ-11 cells infected in Huh7.5 cell assessed as viral-induced colony formation efficiency at 10 uM after 10 to 14 days in presence of 125 ug/ml G4182008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID533319Selectivity Index, ratio of CC50 for RP7 cell harboring HCV genotype 1b to EC50 for HCV genotype 1b in RP7 replicon cell2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID598283Antiprotozoan activity against Entamoeba histolytica HM1-IMSS trophozoites after 48 hrs2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID1709790Binding affinity to GST-tagged human STAT3 using 5-carboxyfluorescein labelled peptide incubated for 1 hr by fluorescence polarization assay
AID1194389Trichomonicidal activity against Trichomonas vaginalis GT3 compound treated for 48 hrs followed by incubation for 48 hrs in compound-free medium by cell counting2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Synthesis of nitro(benzo)thiazole acetamides and in vitro antiprotozoal effect against amitochondriate parasites Giardia intestinalis and Trichomonas vaginalis.
AID533321Selectivity Index, ratio of CC50 for TIZ-9 cell harboring HCV genotype 1b to EC50 for HCV genotype 1b in TIZ-9 replicon cell2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID598286Antimalarial activity against Plasmodium berghei schizonts isolated from parasitized erythrocytes infected Wistar rat measured 16 hrs post compound exposure2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID642457Cytotoxicity against human Ava5 cells after 3 days by neutral red dye assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication.
AID533317Cytotoxicity against human NTZ-11 cell harboring HCV genotype 1b after 4 days by neutral red dye uptake assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID642459Antiviral activity against HCV genotype 1a infected in Huh7.5 cells assessed as inhibition of viral replication after 3 days by blot hybridization analysis2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication.
AID1431016Drug level in Sprague-Dawley rat treated with RM5061 at 6.4 mg/kg, iv measured at 0.25 to 1 hrs post dose2017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs.
AID598288Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Giardia intestinalis IMSS:0696:12011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID598284Antileishmanial activity against Leishmania mexicana MHOM/MX/ISETGS promastigotes after 72 hrs by neubauer chamber2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID606894Protein binding in human plasma2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication.
AID1709758Inhibition of IL-6 induced STAT3 transcriptional activity in human HEK-Blue IL-6 cells assessed as secreted embryonic alkaline phosphatase reporter gene expression measured after 20 hrs by microplate reader
AID533313Antiviral activity against HCV genotype 1b in RP7 replicon cell after 4 days by blot hybridization analysis2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID618735Antimicrobial activity against replicating Mycobacterium tuberculosis2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H₃₇Rv.
AID598289Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Trichomonas vaginalis GT32011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID606882Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication.
AID598313Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Trypanosoma cruzi MHOM/MX/1994/Ninoa2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID325503Growth inhibition of Giardia lamblia2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
A novel Giardia lamblia nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides.
AID546707Antimicrobial activity against Staphylococcus epidermidis CAV1005 at 25 ug/ml under aerobic condition by microdilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces.
AID533318Cytotoxicity against human TIZ-9 cell harboring HCV genotype 1b after 4 days by neutral red dye uptake assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID606884Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in intracellular viral DNA measured 24 hrs after last dose2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication.
AID431992Antimycobacterial activity against Mycobacterium tuberculosis H37Rv in 7H9 liquid medium after 7 days2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance.
AID1709755Inhibition of IL-6 induced STAT3 transcriptional activity in human HEK-Blue IL-6 cells assessed as secreted embryonic alkaline phosphatase reporter gene expression at 10 uM by microplate reader
AID533327Antiviral activity against HCV genotype 1b obtained from TIZ-9 cells infected in Huh7.5 cell assessed as viral-induced colony formation efficiency at 10 uM after 10 to 14 days in presence of 125 ug/ml G4182008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID546703Antimicrobial activity against Staphylococcus epidermidis 5179 by microdilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces.
AID546702Antimicrobial activity against Staphylococcus epidermidis 9142 by microdilution method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces.
AID1431156Drug level in Beagle dog plasma treated with RM-5061 up to 25 mg/kg administered orally as gelatin capsule once daily for 28 days measured on day 1 and 292017European journal of medicinal chemistry, Jan-27, Volume: 126Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs.
AID598281Antiprotozoan activity against Giardia intestinalis IMSS:0696:1 trophozoites after 48 hrs2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID598314Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Plasmodium berghei2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID1709761Cytotoxicity against human HEK 293T cells assessed as cell growth inhibition at 10 uM measured after 48 hrs by MTT assay
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (56)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (1.79)18.2507
2000's17 (30.36)29.6817
2010's24 (42.86)24.3611
2020's14 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (7.02%)5.53%
Reviews1 (1.75%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (91.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research Highlights

Pharmacokinetics (6)

ArticleYear
Design, Synthesis, and Pharmacokinetic Evaluation of O-Carbamoyl Tizoxanide Prodrugs.
Medicinal chemistry (Shariqah (United Arab Emirates)), Volume: 18, Issue: 1
2022
Pharmacokinetics, Metabolism, and Partial Biodistribution of "Pincer Therapeutic" Nitazoxanide in Mice following Pulmonary Delivery of Inhalable Particles.
Molecular pharmaceutics, 04-03, Volume: 14, Issue: 4
2017
Development of a method by UPLC-MS/MS for the quantification of tizoxanide in human plasma and its pharmacokinetic application.
Bioanalysis, Volume: 4, Issue: 8
2012
The pharmacokinetics of nitazoxanide active metabolite (tizoxanide) in goats and its protein binding ability in vitro.
Journal of veterinary pharmacology and therapeutics, Volume: 33, Issue: 2
2010
Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d.
International journal of clinical pharmacology and therapeutics, Volume: 40, Issue: 5
2002
Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses.
International journal of clinical pharmacology and therapeutics, Volume: 40, Issue: 5
2002
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (5)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5
2019
Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs.
European journal of medicinal chemistry, Jan-27, Volume: 126
2017
Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication.
Journal of medicinal chemistry, Dec-22, Volume: 54, Issue: 24
2011
Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d.
International journal of clinical pharmacology and therapeutics, Volume: 40, Issue: 5
2002
Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses.
International journal of clinical pharmacology and therapeutics, Volume: 40, Issue: 5
2002
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (4)

ArticleYear
Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, Aug-01, Volume: 1228
2023
Design, Synthesis, and Pharmacokinetic Evaluation of O-Carbamoyl Tizoxanide Prodrugs.
Medicinal chemistry (Shariqah (United Arab Emirates)), Volume: 18, Issue: 1
2022
Prophylactic and therapeutic efficacy of nitazoxanide against Cryptosporidium parvum in experimentally challenged neonatal calves.
Veterinary parasitology, Mar-09, Volume: 160, Issue: 1-2
2009
Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d.
International journal of clinical pharmacology and therapeutics, Volume: 40, Issue: 5
2002
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Interactions (1)

ArticleYear
Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir.
Antiviral research, Volume: 180
2020
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]